INTRODUCTION: CNS embryonal tumors comprise a group of highly malignant neoplasms with a wide spectrum of histomorphological entities that includes Medulloblastoma (MB), Atypical Teratoid/Rhabdoid Tumor (AT/RT), Neuroblastoma (NB), Ganglioneuroblastoma (GNB), Embryonal Tumor with Multilayered Rosettes (ETMR), and the embryonal tumor-Not Otherwise Specified (NOS). The entity ETMR includes previously described histopathologic patterns-Embryonal Tumor with Abundant Neuropil and True Rosettes (ETANTR), Ependymoblastoma (EBL), and Medulloepithelioma (MEPL). Based on the histopathological similarities (multilayered rosettes) among ETANTR, EBL, and MEPL, as well as uniform clinical behavior and common molecular genetic characteristics, the WHO revision has created a new entity, "ETMR." Immunoreactivity of LIN28A has been identified as a sensitive tool for the diagnosis of this entity. Since there is a paucity of literature regarding immunoreactivity of LIN28A across all embryonal CNS tumors, the present study was undertaken. MATERIALS AND METHODS: During the 5-year study period (2012 to 2016), all the embryonal tumors (MB, AT/RT, other embryonal tumors-ETANTR, MEPL, PNET) that had been earlier diagnosed in the department of neuropathology (cases operated in our institute as well as received as referral) were reviewed. The archived Hematoxylin and Eosin (H&E) and the available immunohistochemistry (IHC) sections were studied. Further, for the other embryonal tumors where the paraffin blocks were available, an extended panel of IHC was performed for confirming the diagnosis of embryonal tumor and only confirmed cases were included in the study. The demographic details of the study cohort were noted. IHC for LIN28A was performed on conventional sections. RESULTS: A total of 396 cases of embryonal tumors including 302 MB, 72 AT/RT, and 22 other embryonal tumors were diagnosed during the study period. Among these, 80 MB, 35 AT/RT, 4 ETANTR, 1 MEPL, 4 NB, 2 GNB, and 1 CNS embryonal tumor-NOS (total-127) were included for the study. LIN28A immunoreactivity was absent in all MB, GNB, NB, and CNS embryonal tumors-NOS whereas all cases of ETMR (4 ETANTR, 1 MEPL) and 8/35 (23%) of AT/RT showed immunopositivity for LIN28A, which was patchy and distinct in most of the cases of ETMR. CONCLUSION: Our study reiterates that LIN28A is a sensitive IHC marker for the diagnosis of ETMR. We also show that among CNS embryonal tumors, LIN28A is not specific to ETMRs and such immunoreactivity can also be seen in a proportion of AT/RTs.
INTRODUCTION: CNS embryonal tumors comprise a group of highly malignant neoplasms with a wide spectrum of histomorphological entities that includes Medulloblastoma (MB), Atypical Teratoid/Rhabdoid Tumor (AT/RT), Neuroblastoma (NB), Ganglioneuroblastoma (GNB), Embryonal Tumor with Multilayered Rosettes (ETMR), and the embryonal tumor-Not Otherwise Specified (NOS). The entity ETMR includes previously described histopathologic patterns-Embryonal Tumor with Abundant Neuropil and True Rosettes (ETANTR), Ependymoblastoma (EBL), and Medulloepithelioma (MEPL). Based on the histopathological similarities (multilayered rosettes) among ETANTR, EBL, and MEPL, as well as uniform clinical behavior and common molecular genetic characteristics, the WHO revision has created a new entity, "ETMR." Immunoreactivity of LIN28A has been identified as a sensitive tool for the diagnosis of this entity. Since there is a paucity of literature regarding immunoreactivity of LIN28A across all embryonal CNS tumors, the present study was undertaken. MATERIALS AND METHODS: During the 5-year study period (2012 to 2016), all the embryonal tumors (MB, AT/RT, other embryonal tumors-ETANTR, MEPL, PNET) that had been earlier diagnosed in the department of neuropathology (cases operated in our institute as well as received as referral) were reviewed. The archived Hematoxylin and Eosin (H&E) and the available immunohistochemistry (IHC) sections were studied. Further, for the other embryonal tumors where the paraffin blocks were available, an extended panel of IHC was performed for confirming the diagnosis of embryonal tumor and only confirmed cases were included in the study. The demographic details of the study cohort were noted. IHC for LIN28A was performed on conventional sections. RESULTS: A total of 396 cases of embryonal tumors including 302 MB, 72 AT/RT, and 22 other embryonal tumors were diagnosed during the study period. Among these, 80 MB, 35 AT/RT, 4 ETANTR, 1 MEPL, 4 NB, 2 GNB, and 1 CNS embryonal tumor-NOS (total-127) were included for the study. LIN28A immunoreactivity was absent in all MB, GNB, NB, and CNS embryonal tumors-NOS whereas all cases of ETMR (4 ETANTR, 1 MEPL) and 8/35 (23%) of AT/RT showed immunopositivity for LIN28A, which was patchy and distinct in most of the cases of ETMR. CONCLUSION: Our study reiterates that LIN28A is a sensitive IHC marker for the diagnosis of ETMR. We also show that among CNS embryonal tumors, LIN28A is not specific to ETMRs and such immunoreactivity can also be seen in a proportion of AT/RTs.
Authors: Dominik Sturm; Brent A Orr; Umut H Toprak; Volker Hovestadt; David T W Jones; David Capper; Martin Sill; Ivo Buchhalter; Paul A Northcott; Irina Leis; Marina Ryzhova; Christian Koelsche; Elke Pfaff; Sariah J Allen; Gnanaprakash Balasubramanian; Barbara C Worst; Kristian W Pajtler; Sebastian Brabetz; Pascal D Johann; Felix Sahm; Jüri Reimand; Alan Mackay; Diana M Carvalho; Marc Remke; Joanna J Phillips; Arie Perry; Cynthia Cowdrey; Rachid Drissi; Maryam Fouladi; Felice Giangaspero; Maria Łastowska; Wiesława Grajkowska; Wolfram Scheurlen; Torsten Pietsch; Christian Hagel; Johannes Gojo; Daniela Lötsch; Walter Berger; Irene Slavc; Christine Haberler; Anne Jouvet; Stefan Holm; Silvia Hofer; Marco Prinz; Catherine Keohane; Iris Fried; Christian Mawrin; David Scheie; Bret C Mobley; Matthew J Schniederjan; Mariarita Santi; Anna M Buccoliero; Sonika Dahiya; Christof M Kramm; André O von Bueren; Katja von Hoff; Stefan Rutkowski; Christel Herold-Mende; Michael C Frühwald; Till Milde; Martin Hasselblatt; Pieter Wesseling; Jochen Rößler; Ulrich Schüller; Martin Ebinger; Jens Schittenhelm; Stephan Frank; Rainer Grobholz; Istvan Vajtai; Volkmar Hans; Reinhard Schneppenheim; Karel Zitterbart; V Peter Collins; Eleonora Aronica; Pascale Varlet; Stephanie Puget; Christelle Dufour; Jacques Grill; Dominique Figarella-Branger; Marietta Wolter; Martin U Schuhmann; Tarek Shalaby; Michael Grotzer; Timothy van Meter; Camelia-Maria Monoranu; Jörg Felsberg; Guido Reifenberger; Matija Snuderl; Lynn Ann Forrester; Jan Koster; Rogier Versteeg; Richard Volckmann; Peter van Sluis; Stephan Wolf; Tom Mikkelsen; Amar Gajjar; Kenneth Aldape; Andrew S Moore; Michael D Taylor; Chris Jones; Nada Jabado; Matthias A Karajannis; Roland Eils; Matthias Schlesner; Peter Lichter; Andreas von Deimling; Stefan M Pfister; David W Ellison; Andrey Korshunov; Marcel Kool Journal: Cell Date: 2016-02-25 Impact factor: 41.582
Authors: Stefan M Pfister; Andrey Korshunov; Marcel Kool; Martin Hasselblatt; Charles Eberhart; Michael D Taylor Journal: Acta Neuropathol Date: 2010-09-30 Impact factor: 17.088
Authors: Andrey Korshunov; Marc Remke; Marco Gessi; Marina Ryzhova; Thomas Hielscher; Hendrik Witt; Vivienne Tobias; Anna Maria Buccoliero; Iacopo Sardi; Marina Paola Gardiman; Jose Bonnin; Bernd Scheithauer; Andreas E Kulozik; Olaf Witt; Sverre Mork; Andreas von Deimling; Otmar D Wiestler; Felice Giangaspero; Marc Rosenblum; Torsten Pietsch; Peter Lichter; Stefan M Pfister Journal: Acta Neuropathol Date: 2010-04-21 Impact factor: 17.088
Authors: Meihua Li; Kyle F Lee; Yuntao Lu; Ian Clarke; David Shih; Charles Eberhart; V Peter Collins; Tim Van Meter; Daniel Picard; Limei Zhou; Paul C Boutros; Piergiorgio Modena; Muh-Lii Liang; Steve W Scherer; Eric Bouffet; James T Rutka; Scott L Pomeroy; Ching C Lau; Michael D Taylor; Amar Gajjar; Peter B Dirks; Cynthia E Hawkins; Annie Huang Journal: Cancer Cell Date: 2009-12-08 Impact factor: 31.743
Authors: Marco Gessi; Felice Giangaspero; Libero Lauriola; Marina Gardiman; Bernd W Scheithauer; William Halliday; Cynthia Hawkins; Marc K Rosenblum; Peter C Burger; Charles G Eberhart Journal: Am J Surg Pathol Date: 2009-02 Impact factor: 6.394
Authors: Andrey Korshunov; Marina Ryzhova; David T W Jones; Paul A Northcott; Peter van Sluis; Richard Volckmann; Jan Koster; Rogier Versteeg; Cynthia Cowdrey; Arie Perry; Daniel Picard; Marc Rosenblum; Felice Giangaspero; Eleonora Aronica; Ulrich Schüller; Martin Hasselblatt; V Peter Collins; Andreas von Deimling; Peter Lichter; Annie Huang; Stefan M Pfister; Marcel Kool Journal: Acta Neuropathol Date: 2012-11-16 Impact factor: 17.088
Authors: Tara Spence; Patrick Sin-Chan; Daniel Picard; Mark Barszczyk; Katharina Hoss; Mei Lu; Seung-Ki Kim; Young-Shin Ra; Hideo Nakamura; Jason Fangusaro; Eugene Hwang; Erin Kiehna; Helen Toledano; Yin Wang; Qing Shi; Donna Johnston; Jean Michaud; Milena La Spina; Anna Maria Buccoliero; Dariusz Adamek; Sandra Camelo-Piragua; V Peter Collins; Chris Jones; Nabil Kabbara; Nawaf Jurdi; Pascale Varlet; Arie Perry; David Scharnhorst; Xing Fan; Karin M Muraszko; Charles G Eberhart; Ho-Keung Ng; Sridharan Gururangan; Timothy Van Meter; Marc Remke; Lucie Lafay-Cousin; Jennifer A Chan; Nongnuch Sirachainan; Scott L Pomeroy; Steven C Clifford; Amar Gajjar; Mary Shago; William Halliday; Michael D Taylor; Richard Grundy; Ching C Lau; Joanna Phillips; Eric Bouffet; Peter B Dirks; Cynthia E Hawkins; Annie Huang Journal: Acta Neuropathol Date: 2014-05-20 Impact factor: 17.088
Authors: Greta Foiani; Maria Teresa Mandara; Antonio Carminato; Erica Melchiotti; Michela Corrò; Marta Vascellari Journal: Front Vet Sci Date: 2022-08-25